Close of Retail Offer

RNS Number : 9564L

Yourgene Health PLC

06 January 2023

 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 2014/596/EU (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN .

Yourgene Health plc

("Yourgene" or the "Company")

Close of Retail Offer

Yourgene Health plc (AIM: YGEN), a leading international molecular diagnostics group, announces that, further to the announcement made at 11:00 a.m. on 22 December 2022, the Retail Offer conducted via the BookBuild platform has now closed.

The results of the Retail Offer and the resulting total voting rights in the Company's shares will both be confirmed following the conclusion of the General Meeting of the Company to be held at 4.00 p.m. on 9 January 2023.

Admission of the Second Admission Shares to be issued under the Retail Offer is expected to take place at 8.00 a.m. on 11 January 2023. Completion of the Retail Offer is conditional, inter alia, upon the completion of the Placing.

Capitalised terms used in this announcement have the meanings given to them in the Circular published on 23 December 2022, unless the context provides otherwise.

Enquiries:

Yourgene Health plc Lyn Rees (Chief Executive Officer)	Tel: [phone] [e-mail]
Barry Hextall (Chief Financial Officer)
Joanne Cross (Director of Marketing)
Cairn Financial Advisers LLP (NOMAD)	Tel: [phone]
Liam Murray/ James Caithie/ Ludovico Lazzaretti
Singer Capital Markets (Corporate Broker)	Tel: [phone]
Aubrey Powell/ Tom Salvesen/ George Tzimas/ Alex Emslie
Walbrook PR Ltd (Media and Investor Relations)	Tel: [phone] or [e-mail]
Paul McManus/ Lianne Applegarth/ Alice Woodings	Mob: [phone]

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops integrated genomic technologies and services enabling precision medicine. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID-19 testing service.

In August 2020, Yourgene acquired Coastal Genomics , Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 

END

 

 

MSCNKABNKBKDCDK